A new innovation project “Personae” will provide patients with depression with easier access to personalized digital treatment via Monsenso’s digital health platform. The project uses patient-reported outcomes and AI to screen patients and provide treatment tailored to each patient’s needs.
Investor News No. 1-2023
According to the WHO, more than a billion people worldwide suffer from mental disorders, but the number of people receiving help is shockingly small. In western Europe, for example, only half of citizens with anxiety or depression receive appropriate treatment. At the same time, the healthcare system is challenged by a shortage of medical professionals.
Therefore, Innovation Fund Denmark is funding the development of a personalized treatment based on Monsenso’s digital health solution, which uses artificial intelligence to tailor treatment to the needs of the individual patient.
Today, digital programs offer evidence-based treatment to citizens with depression, for example in the Danish clinic “Internet Psychiatry”. Research shows that such programs have the same effect as physical therapy sessions on citizens with mild to moderate depression. The potential is huge, with thousands of citizens on waiting lists or not receiving any relevant support at all. However, delivering a personalized intervention for everyone is challenging. Some patients benefit from a fully automated, digital treatment regimen, others require their treatment regimen to be supported by a psychologist, and still other patients with complex life situations require physical conversations with their healthcare providers.
“The project enables us to use artificial intelligence, which in cooperation with Monsenso’s digital health solution and online psychiatric institutions, can ensure that more people have access to the right treatment quickly. This next-generation digital treatment will make it much easier to offer a fully or partially digital treatment that meets the needs of each individual,” says Kim Mathiasen, research director at the Center for Digital Psychiatry, who leads the Personae project.
“We see great potential in this project. It enables us to further develop and further validate our digital health solution. It will improve the way we use people’s own health and behavioral data to motivate them to adjust their treatment and support clinical decision-making at scale,” says Thomas Lethenborg, CEO of Monsenso.
“The unique patient-reported data generated from the screening and continuous use of Monsenso’s solution in internet psychiatric settings is a fantastic basis for the development, training and validation of algorithms to automate decision support and optimize treatment pathways,” says Pepijn Van de Ven, Professor at the University of Limerick.
The primary goal of the project is the development of intelligent adaptations of the treatment contents to the symptoms and life situations of the patients. The solution should be able to detect early signs of discontinuation and support patient and healthcare provider treatment decisions. The AI solutions will be integrated into both the public internet psychiatric clinic operated by the Center for Digital Psychiatry and Monsenso’s digital health solution.
The project is led by the Center for Digital Psychiatry, which is a pioneer of internet-based therapy in terms of development, research and operations in the Danish and international context. This project combines their research and extensive clinical experience with Monsenso’s capabilities and commercial platform, as well as the unique capabilities in artificial intelligence for mental health at the University of Limerick.
Investment and Cooperation Agreements for the project, previously mentioned in Company Announcement 15-2022 upon receipt of the grant letter, have now been signed and the project will commence on May 1, 2023. The project will not impact Monsenso’s financial expectations for 2023 , but is expected to contribute to growth in 2023 and beyond.
Project title: Personae – Personalized digital treatment of depression
Total budget: 22.1 million DKK
Investment by Innovation Fund Denmark: DKK 16.5 million
Net contribution to Monsenso: DKK 3.9 million
Duration: 4 years
About the partners
The Center for Digital Psychiatry in the Region of Southern Denmark works to ensure that all Danes have easy and equal access to mental health. In a Danish and international context, the Center for Digital Psychiatry is a pioneer in using digital solutions for mental health promotion and psychiatric treatment and is an expert in matching the current needs of psychiatry with the right digital technology.
The University of Limerick, Department of Electronic & Computer Engineering, has a high level of expertise in research and teaching in information and communication technology. The Department of Electronic & Computer Engineering is at the forefront of artificial intelligence research for internet-based therapies.
The project also involves Odense University Hospital, the Danish Depression Association and the strategic innovation agency Is It a Bird.
Phone +45 21 29 88 27
Email: [email protected]
North CEF A/S
Phone +45 20 72 02 00
Email: [email protected]
Monsenso is an innovative technology company offering a digital healthcare solution for decentralized studies, remote patient monitoring and treatment support. Our mission is to help bring better health to more people, at a lower cost, by digitally supporting treatment and leveraging patient-reported outcome data. Our solution helps optimize treatment and provides a detailed view of an individual’s health by capturing outcome, adherence and behavioral data. It connects individuals, caregivers and healthcare providers to enable personalized treatment, remote care and early intervention. We work with healthcare and social care organizations, pharmaceutical companies and leading researchers around the world to deliver solutions that fit into the lives of patients and healthcare professionals. To learn more, visit www.monsenso.com
Download Announcement PDF attachments.pdfPatient with smartphone.jpgClinician with Clinical Web portal.jpg
© Ritzau Denmark, source Ritzau English Regulatory Releases